|Year : 2018 | Volume
| Issue : 4 | Page : 198-201
Sling incision is not always sufficient: A case series
Philippe E Zimmern1, Himanshu Aggarwal2, Feras Alhalabi1
1 The University of Texas Southwestern Medical Center, Dallas, TX, USA
2 Baptist Medicine Center South, Montgomery, AL, USA
|Date of Web Publication||23-Jul-2018|
Philippe E Zimmern
The University of Texas Southwestern Medical Center, 5323 Harry Hines Blvd., Dallas, TX
Source of Support: None, Conflict of Interest: None
Objectives: To review various erroneous diagnoses assigned to symptomatic women after MUS incision, and report our outcomes after MUS excision in these women. Materials and Methods: Following IRB approval, a retrospective review of a prospectively collected MUS removal database was performed for non-neurogenic women who presented with continued LUTS despite a prior sling incision. Data reviewed by a neutral investigator not involved in patient care included demographics, presenting symptomatology, and outcomes after sub-urethral sling excision. Results: From 2006-2015, 18 patients were identified. Mean age was 55 + 12 years. Median time from initial placement to sling incision was 12 (range 1-108) months. Following sling incision, residual LUTS were treated with various therapies but without LUTS resolution. Indications for sling excision were obstruction (3), obstruction and pain (2), persistent vaginal pain/dyspareunia (9), recurrent vaginal exposure/dyspareunia (2), worsening urgency incontinence (1) and mixed urinary incontinence (1). Median time from sling incision to sling excision was 55 (range 5-146) months. Median follow-up after MUS excision was 12 months (range 6-45 months). Obstruction (5) and exposure (2) were all cured. Vaginal pain and dyspareunia improved in 8 of 11 women and UUI improved in one. Three women had persistent SUI and 1 developed recurrent SUI. Two women were treated satisfactorily with bulking agents, one with fascial sling and one with bulking agent followed by a fascial sling. Conclusions: Sling incision may not always resolve LUTS. In a subset of women, sling excision may eventually be needed, with variable outcomes.
Keywords: Bladder outlet obstruction, sling excision, sling incision
|How to cite this article:|
Zimmern PE, Aggarwal H, Alhalabi F. Sling incision is not always sufficient: A case series. Urol Sci 2018;29:198-201
| Introduction|| |
Although mid-urethral sling (MUS) is the most commonly performed procedure for female stress urinary incontinence (SUI),, it remains a sling procedure which, as such, can be fraught with secondary complications, including lower urinary tract dysfunction, vaginal pain, and dyspareunia. There is available information on postoperative urinary retention rate after MUS which has been reported as high as 25%–43%.,,, Persistent voiding dysfunction beyond 4 weeks has also been reported in various studies, including a randomized controlled trial (trial of MUS [TOMUS]) by the Urinary Incontinence Treatment Network group.,,, Other complications of MUS have also been described, including vaginal exposure ranging from 3% to 21%,, dyspareunia/vaginal pain 3% to 8%,, and worsening/persistent urgency/urgency urinary incontinence (UUI) 10% to 14% of patients., In the E-TOMUS, MUS patients were found to be at continuous risk of mesh exposure with 2% additional patients developing sling exposures between 2 and 5 years of follow-up.
Postoperative voiding dysfunction and the possibility of bladder outlet obstruction (BOO) from MUS are issues not always easy to confirm clinically, despite the accepted tenet that the new onset of voiding dysfunction after a sling should raise concern for BOO. Several studies have described a variety of surgical techniques to relieve obstruction including urethral dilation, sling stretching, sling incision, partial sling excision, and urethrolysis, with variable outcomes , Among these different techniques, sling incision offers the least invasive approach, with a timing ranging from 3 to 12 months after MUS placement. The goal is to relieve the obstruction while preserving some continence. However, there are limited data comparing the merit of this “minimalistic” approach against a more involved approach involving suburethral sling excision or a more complete urethrolysis  to definitively address the obstructive process. Furthermore, once the MUS incision has been done, it is conventionally assumed that BOO has been relieved, and so, these patients are generally considered “unobstructed.” For this reason, very little information is known regarding persistent lower urinary tract symptoms (LUTSs) following just a sling incision. A recent series of women seen after MUS incision who experienced residual LUTS, vaginal pain/dyspareunia, and/or vaginal exposure of sling mesh called our attention to this often overlooked condition.
The purpose of this study was to review the various erroneous diagnoses assigned to these women after MUS incision, including idiopathic bladder overactivity, and to report herein our approach to evaluation and mid-term outcome after MUS excision in these women.
| Materials and Methods|| |
We reviewed an institutional review board approved database of consecutive women who underwent MUS removal from 2006 to 2015. Inclusion criteria included women who presented with continued LUTS, vaginal pain/dyspareunia, and/or recurrent vaginal extrusion of MUS after a prior MUS incision at other institutions. Patients with combined vaginal mesh removal along with MUS removal and with more than one MUS removal were excluded. All data originated from an electronic medical record and were reviewed and updated by a neutral investigator not involved in patient care (HA).
Data collection included demographics, presenting symptoms, physical examination findings, prior procedures including timing and type of MUS placement, timing of MUS incision, other diagnoses assigned to patients along with other treatments done before presentation to our clinic, and outcome after MUS excision. Preoperative evaluation after MUS incision and before consideration for MUS excision included voiding cystourethrogram (VCUG), translabial ultrasound [Figure 1], and/or multichannel urodynamics as indicated. All women underwent vaginal excision of the suburethral portion of the MUS by one surgeon (PZ) with an already reported technique.
|Figure 1: Translabial three-dimensional ultrasound reconstruction demonstrating the course of a transobturator tape with left- and right-sided arms separated by a groove at the 5–6 o'clock position inferior to the urethral lumen where the prior incision took place. The operative note of this patient did not detail the site of the mid-urethral sling incision|
Click here to view
Resolution of pain and dyspareunia was defined as complete resolution meaning being pain-free and with no discomfort during intercourse. Urinary obstruction was determined by subjective voiding symptoms, VCUG findings, and urodynamic pressure-flow testing. Continence or dry was defined by the patient reporting no or rare episodes of SUI which were not bothersome. Descriptive statistics were used to analyze the data.
| Results|| |
From 2006 to 2015, 18 out of 23 women who had MUS incision before presenting to our clinic were identified from a database of 373 patients who underwent one vaginal suburethral MUS excision only. Mean age was 55 + 12 years, with a mean body mass index of 29 + 7. Median time from initial MUS placement to sling incision at outside facilities was 12 months (range 1–108).
After sling incision, several patients were treated for conditions later on attributed to their residual sling but not suspected at the time by their treating team. In particular, four patients were treated with anticholinergic medications for overactive bladder/UUI, and one of them subsequently received a sacral neuromodulator. Four patients were treated with anticholinergic medications and diagnosed with pelvic pain: one of them underwent diagnostic laparoscopy to exclude endometriosis, one received pelvic floor therapy without any relief, and one also had persistent SUI but failed bulking agents. Two patients were diagnosed with voiding dysfunction, with one on clean intermittent catheterization (CIC).
Preoperative evaluation, before sling excision by us, included standing VCUG in 16 women (with mid-urethral kinking/distortion found on lateral voiding views in 6), translabial ultrasound in 2 [Figure 1], and multichannel urodynamics confirming obstruction  (4) and Valsalva voiding (2).
Indications for MUS excision included persistent obstructive symptoms, alone (3) or along with pain (2), persistent vaginal pain along with dyspareunia (9), recurrent vaginal exposure causing dyspareunia (2) [Figure 2], worsening UUI (1), and mixed urinary incontinence (1).
Median time from MUS incision to MUS excision was 55 months (range 5–146). Type of sling included transobturator sling (8), retropubic sling (6), and minisling (4). Median follow-up after MUS excision was 12 months (6–45 months).
All women with exposure (2) and obstruction (5) were cured including the one on CIC before who resumed normal voiding after MUS excision. Vaginal pain and dyspareunia improved in 8 of 11 women and UUI improved in 1. Three women had persistent bothersome SUI and 1 developed bothersome recurrent SUI. Two women with SUI were treated satisfactorily with bulking agents, one with rectus fascial sling, and one with bulking agent followed by a rectus fascial sling.
| Discussion|| |
This case series on sling excision after prior sling incision alerts to the fact that a subset of women may experience residual LUTS including UUI, obstructive voiding symptoms, vaginal extrusion, and/or pain/dyspareunia after MUS incision. Because of the prior history of MUS incision, it is commonly assumed by the treating team that the MUS is not causing that persistent symptomatology. There is typically a substantial delay in recognition that the incised MUS can be causative of these residual symptoms. During that phase, a range of therapies have been offered to these women with no durable benefit. Therefore, it is important to recognize that not all MUS incisions will be successful in relieving LUTS or pain/dyspareunia and that, following detailed evaluation and possible specialized testing, MUS excision may have to be considered in these women with residual symptomatology.
By design, any sling regardless of its origin (synthetic, cadaveric, allograft, and autologous) may induce some degree of bladder outflow obstruction (BOO) to be effective. When this occurs, de novo storage and/or obstructive symptoms can develop. The implications of a postoperative diagnosis of BOO are significant because it means that a procedure to either loosen the sling or remove it suburethrally needs to be contemplated fairly soon to improve voiding and avoid the risk of bladder wall damage; however, this needs to be done while trying to maintain the urinary continence level generally achieved by the MUS placement. Studies have shown that preoperative parameters such as patient demographics and urodynamic findings do not predict which patients are more likely to develop these symptoms. However, one study reported that patients with preexisting voiding symptoms, retropubic sling type, and concurrent prolapse surgery were more likely to need MUS revision.
Many authors have recommended sling incision as the preferred method of managing these women because of fear of recurrence of SUI along with the fact that it offers a minimally invasive option. However, the data on MUS incision outcome are limited and based on short follow-up. One study reported that out of 1175 patients who underwent placement of a tension-free retropubic mesh sling, 1.9% underwent sling release for voiding dysfunction and/or urge urinary incontinence. All patients with voiding dysfunction had resolution, with 13% developing recurrent SUI. In a recent study on 3300 women who underwent MUS placement, about 3% patients underwent sling revision at follow-up of 8 months. However, the follow-up was at 6 weeks only. Another study compared outcomes after sling incision, suburethral sling excision, or complete retropubic urethrolysis after MUS in 44 patients. Overall 93% patients had one of these three techniques performed for voiding dysfunction and 73% experienced resolution of symptoms. SUI recurred or persisted in 34% of patients. There was no difference in outcomes between the three techniques. However, this study offered a follow-up on only three-quarter of the patients. Some authors have recommended that a midline incision within a year of MUS placement may be more effective than a late incision after a year of MUS placement as far as relieving the obstructive symptoms (91% vs. 71%, P = 0.01), with no difference noted between early and late sling incision for recurrent SUI. However, this study did not report on outcomes of these patients beyond 1 year.
We report our experience in 18 women who continued to have symptoms after MUS incision. These symptoms were assigned to a variety of differential diagnoses, which in turn prompted a range of therapies that were of no benefit to these women as their original MUS was still the source of their symptomatology. A major limitation of the current literature on sling incision is that the data on how many patients improve after sling incision are unknown as we only see women who are referred or self-referred themselves to us after failed treatments. In addition, the reported number of patients requiring sling excision or urethrolysis is underreported. In a large nationwide study of 9000 patients who underwent tension-free vaginal tape, 50 (0.6%) underwent MUS incision procedure for urinary retention. Out of those, 49% were completely cured, but 12% had persistent retention requiring urethrolysis. In another recent study, about 70% of patients reported partial or complete improvement after sling revision. To the best of our knowledge, there is no study describing the incidence of vaginal pain/dyspareunia after MUS and its resolution/persistence after MUS incision alone. We observed that 11 women reported persistent dyspareunia/vaginal pain after MUS incision. Eight of these 11 improved after complete MUS excision at a median follow-up of 12 months. Some of these patients were subsequently referred to pelvic floor therapist for further management.
| Conclusions|| |
This is a retrospective series of women who remained symptomatic after MUS incision and were assigned incorrect diagnoses. The practicing provider should be vigilant of continued symptoms in these women, consider further investigations to determine if there is a link with the original sling placement, and if so, consider MUS excision. MUS excision can provide substantial relief in many of these women.
Financial support and sponsorship
Conflicts of interest
There are no conflicts of interest.
| References|| |
Guerette NL, Bena JF, Davila GW. Transobturator slings for stress incontinence: Using urodynamic parameters to predict outcomes. Int Urogynecol J Pelvic Floor Dysfunct 2008;19:97-102.
Schierlitz L, Dwyer PL, Rosamilia A, Murray C, Thomas E, De Souza A, et al.
Effectiveness of tension-free vaginal tape compared with transobturator tape in women with stress urinary incontinence and intrinsic sphincter deficiency: A randomized controlled trial. Obstet Gynecol 2008;112:1253-61.
Dörflinger A, Monga A. Voiding dysfunction. Curr Opin Obstet Gynecol 2001;13:507-12.
Richter HE, Albo ME, Zyczynski HM, Kenton K, Norton PA, Sirls LT, et al.
Retropubic versus transobturator midurethral slings for stress incontinence. N Engl J Med 2010;362:2066-76.
Brubaker L, Norton PA, Albo ME, Chai TC, Dandreo KJ, Lloyd KL, et al.
Adverse events over two years after retropubic or transobturator midurethral sling surgery: Findings from the trial of midurethral slings (TOMUS) study. Am J Obstet Gynecol 2011;205:498.e1-6.
Partoll LM. Efficacy of tension-free vaginal tape with other pelvic reconstructive surgery. Am J Obstet Gynecol 2002;186:1292-5.
Siddighi S, Karram MM. Surgical and nonsurgical approaches to treat voiding dysfunction following antiincontinence surgery. Curr Opin Obstet Gynecol 2007;19:490-5.
Natale F, La Penna C, Saltari M, Piccione E, Cervigni M. Voiding dysfunction after anti-incontinence surgery. Minerva Ginecol 2009;61:167-72.
Unger CA, Rizzo AE, Ridgeway B. Indications and risk factors for midurethral sling revision. Int Urogynecol J 2016;27:117-22.
Tommaselli GA, Di Carlo C, Formisano C, Fabozzi A, Nappi C. Medium-term and long-term outcomes following placement of midurethral slings for stress urinary incontinence: A systematic review and metaanalysis. Int Urogynecol J 2015;26:1253-68.
Kenton K, Stoddard AM, Zyczynski H, Albo M, Rickey L, Norton P, et al
. 5-year longitudinal followup after retropubic and transobturator mid urethral slings. J Urol 2015;193:203-10.
Aponte MM, Shah SR, Hickling D, Brucker BM, Rosenblum N, Nitti VW, et al.
Urodynamics for clinically suspected obstruction after anti-incontinence surgery in women. J Urol 2013;190:598-602.
Geller EJ. Prevention and management of postoperative urinary retention after urogynecologic surgery. Int J Womens Health 2014;6:829-38.
Molden S, Bracken J, Nguyen A, Harvie HS, White A, Hammil SL, et al.
A retrospective multicenter study on outcomes after midurethral polypropylene sling revision for voiding dysfunction. Female Pelvic Med Reconstr Surg 2010;16:340-4.
Goldman HB. Simple sling incision for the treatment of iatrogenic urethral obstruction. Urology 2003;62:714-8.
Segal J, Steele A, Vassallo B, Kleeman S, Silva AW, Pauls R, et al.
Various surgical approaches to treat voiding dysfunction following anti-incontinence surgery. Int Urogynecol J Pelvic Floor Dysfunct 2006;17:372-7.
Dillon BE, Gurbuz C, Zimmern PE. Long term results after complication of “prophylactic” suburethral tape placement. Can J Urol 2012;19:6424-30.
Defreitas GA, Zimmern PE, Lemack GE, Shariat SF. Refining diagnosis of anatomic female bladder outlet obstruction: Comparison of pressure-flow study parameters in clinically obstructed women with those of normal controls. Urology 2004;64:675-9.
Petros PE, Daneshgari F, Hijaz A. Re: Baseline urodynamic predictors of treatment failure 1 year after mid urethral sling surgery: C. W. Nager, L. Sirls, H. J. Litman, H. Richter, I. Nygaard, T. Chai, S. Kraus, H. Zyczynski, K. Kenton, L. Huang, J. Kusek and G. Lemack for the urinary incontinence treatment network J urol 2011;186:597-603. J Urol 2012;187:2282-3.
Molden S, Patterson D, Tarr M, Sanses T, Bracken J, Nguyen A, et al.
Risk factors leading to midurethral sling revision: A multicenter case-control study. Int Urogynecol J 2010;21:1253-9.
Rardin CR, Rosenblatt PL, Kohli N, Miklos JR, Heit M, Lucente VR, et al.
Release of tension-free vaginal tape for the treatment of refractory postoperative voiding dysfunction. Obstet Gynecol 2002;100:898-902.
South MM, Wu JM, Webster GD, Weidner AC, Roelands JJ, Amundsen CL, et al.
Early vs late midline sling lysis results in greater improvement in lower urinary tract symptoms. Am J Obstet Gynecol 2009;200:564.e1-5.
Laurikainen E, Kiilholma P. A nationwide analysis of transvaginal tape release for urinary retention after tension-free vaginal tape procedure. Int Urogynecol J Pelvic Floor Dysfunct 2006;17:111-9.
[Figure 1], [Figure 2]